MAPKAPK2 and plasma cell myeloma: Compared to p38MAPK the MK2 pathway has been less studied, however, some data suggest that MK2 knockdown reduces in vivo growth of multiple myeloma in mouse models with MK2 overexpression leading to bortezomib and doxorubicin chemoresistance by reducing apoptosis [40].